Central Retinal Artery Occlusion: Visual Outcomes from A Large Northern California Cohort
To assess visual acuity (VA) outcomes in a large cohort of patients diagnosed with non-arteritic central retinal artery occlusion (CRAO), and to ascertain whether time from symptom onset to presentation, presenting visual acuity, or conservative treatment delivery (anterior chamber paracentesis, ocu...
Saved in:
| Published in: | Ophthalmology retina Vol. 8; no. 6; p. 566 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.06.2024
|
| Subjects: | |
| ISSN: | 2468-6530, 2468-6530 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | To assess visual acuity (VA) outcomes in a large cohort of patients diagnosed with non-arteritic central retinal artery occlusion (CRAO), and to ascertain whether time from symptom onset to presentation, presenting visual acuity, or conservative treatment delivery (anterior chamber paracentesis, ocular massage, intraocular pressure lowering drugs, hyperventilation, or some combination of those) impacted ultimate VA outcomes.
Retrospective cohort study.
Participants, and/or Controls: The study included 794 patients who presented with CRAO between 2011 and 2020. Within this cohort, 484 individuals presented within 30 days of symptom onset and had comprehensive documentation regarding the details of their presentation, management, and follow-up at least 90 days post-diagnosis.
Intervention, or Testing: Retrospective chart review was conducted for all patients with a diagnosis of CRAO initially identified via ICD coding, followed by confirmation of diagnosis by two retina specialists. Cases of arteritic CRAO were excluded.
VA recovery, defined as improvement from < 20/200 or worse at presentation to > 20/100 at least 90 days after diagnosis.
Of the 794 identified patients, 712 (89.7%) presented with VA of < 20/200. Similarly, 447 (92.4%) of the 484-patient subset that presented within 30 days and had comprehensive documentation, presented with VA < 20/200. Of the 441 of those patients with documented follow up, 380 (86.2%) remained at that level. Of the 244 patients who presented within 4.5 hours of symptom onset, 227 (93%) presented < 20/200 and 201 (92.6%) of the 217 of those with follow-up data did not improve beyond that threshold. There was no significant difference (p < 0.05) in final VA between patients presenting before versus after 4.5 hours from time of vision loss. There was also no significant difference (p < 0.05) in VA outcomes between patients who did or did not receive conservative treatment.
This large retrospective study further highlights the poor visual prognosis for patients with CRAO. Earlier time to presentation did not seem to impact final VA outcome, nor did conservative treatment efforts. Efficacious evidence-based treatment options are needed for this patient population. |
|---|---|
| AbstractList | To assess visual acuity (VA) outcomes in a large cohort of patients diagnosed with non-arteritic central retinal artery occlusion (CRAO), and to ascertain whether time from symptom onset to presentation, presenting visual acuity, or conservative treatment delivery (anterior chamber paracentesis, ocular massage, intraocular pressure lowering drugs, hyperventilation, or some combination of those) impacted ultimate VA outcomes.
Retrospective cohort study.
Participants, and/or Controls: The study included 794 patients who presented with CRAO between 2011 and 2020. Within this cohort, 484 individuals presented within 30 days of symptom onset and had comprehensive documentation regarding the details of their presentation, management, and follow-up at least 90 days post-diagnosis.
Intervention, or Testing: Retrospective chart review was conducted for all patients with a diagnosis of CRAO initially identified via ICD coding, followed by confirmation of diagnosis by two retina specialists. Cases of arteritic CRAO were excluded.
VA recovery, defined as improvement from < 20/200 or worse at presentation to > 20/100 at least 90 days after diagnosis.
Of the 794 identified patients, 712 (89.7%) presented with VA of < 20/200. Similarly, 447 (92.4%) of the 484-patient subset that presented within 30 days and had comprehensive documentation, presented with VA < 20/200. Of the 441 of those patients with documented follow up, 380 (86.2%) remained at that level. Of the 244 patients who presented within 4.5 hours of symptom onset, 227 (93%) presented < 20/200 and 201 (92.6%) of the 217 of those with follow-up data did not improve beyond that threshold. There was no significant difference (p < 0.05) in final VA between patients presenting before versus after 4.5 hours from time of vision loss. There was also no significant difference (p < 0.05) in VA outcomes between patients who did or did not receive conservative treatment.
This large retrospective study further highlights the poor visual prognosis for patients with CRAO. Earlier time to presentation did not seem to impact final VA outcome, nor did conservative treatment efforts. Efficacious evidence-based treatment options are needed for this patient population. To assess visual acuity (VA) outcomes in a large cohort of patients diagnosed with nonarteritic central retinal artery occlusion (CRAO), and to ascertain whether time from symptom onset to presentation, presenting VA, or conservative treatment delivery (anterior chamber paracentesis, ocular massage, intraocular pressure lowering drugs, hyperventilation, or some combination of those) impacted ultimate VA outcomes.PURPOSETo assess visual acuity (VA) outcomes in a large cohort of patients diagnosed with nonarteritic central retinal artery occlusion (CRAO), and to ascertain whether time from symptom onset to presentation, presenting VA, or conservative treatment delivery (anterior chamber paracentesis, ocular massage, intraocular pressure lowering drugs, hyperventilation, or some combination of those) impacted ultimate VA outcomes.Retrospective cohort study.DESIGNRetrospective cohort study.The study included 794 patients who presented with CRAO between 2011 and 2020. Within this cohort, 484 individuals presented within 30 days of symptom onset and had comprehensive documentation regarding the details of their presentation, management, and follow-up ≥ 90 days postdiagnosis.SUBJECTSThe study included 794 patients who presented with CRAO between 2011 and 2020. Within this cohort, 484 individuals presented within 30 days of symptom onset and had comprehensive documentation regarding the details of their presentation, management, and follow-up ≥ 90 days postdiagnosis.Retrospective chart review was conducted for all patients with a diagnosis of CRAO initially identified via International Classification of Diseases coding, followed by confirmation of diagnosis by 2 retina specialists. Cases of arteritic CRAO were excluded.METHODSRetrospective chart review was conducted for all patients with a diagnosis of CRAO initially identified via International Classification of Diseases coding, followed by confirmation of diagnosis by 2 retina specialists. Cases of arteritic CRAO were excluded.Visual acuity recovery, defined as improvement from ≤ 20/200 or worse at presentation to ≥ 20/100 ≥ 90 days after diagnosis.MAIN OUTCOME MEASURESVisual acuity recovery, defined as improvement from ≤ 20/200 or worse at presentation to ≥ 20/100 ≥ 90 days after diagnosis.Of the 794 identified patients, 712 (89.7%) presented with VA of ≤ 20/200. Similarly, 447 (92.4%) of the 484-patient subset that presented within 30 days and had comprehensive documentation presented with VA ≤ 20/200. Of the 441 of those patients with documented follow-up, 380 (86.2%) remained at that level. Of the 244 patients who presented within 4.5 hours of symptom onset, 227 (93%) presented ≤ 20/200 and 201 (92.6%) of the 217 of those with follow-up data did not improve beyond that threshold. There was no significant difference (P < 0.05) in final VA between patients presenting before versus after 4.5 hours from time of vision loss. There was also no significant difference (P < 0.05) in VA outcomes between patients who did or did not receive conservative treatment.RESULTSOf the 794 identified patients, 712 (89.7%) presented with VA of ≤ 20/200. Similarly, 447 (92.4%) of the 484-patient subset that presented within 30 days and had comprehensive documentation presented with VA ≤ 20/200. Of the 441 of those patients with documented follow-up, 380 (86.2%) remained at that level. Of the 244 patients who presented within 4.5 hours of symptom onset, 227 (93%) presented ≤ 20/200 and 201 (92.6%) of the 217 of those with follow-up data did not improve beyond that threshold. There was no significant difference (P < 0.05) in final VA between patients presenting before versus after 4.5 hours from time of vision loss. There was also no significant difference (P < 0.05) in VA outcomes between patients who did or did not receive conservative treatment.This large retrospective study further highlights the poor visual prognosis for patients with CRAO. Earlier time to presentation did not seem to impact final VA outcome, nor did conservative treatment efforts. Efficacious evidence-based treatment options are needed for this patient population.CONCLUSIONSThis large retrospective study further highlights the poor visual prognosis for patients with CRAO. Earlier time to presentation did not seem to impact final VA outcome, nor did conservative treatment efforts. Efficacious evidence-based treatment options are needed for this patient population.The author(s) have no proprietary or commercial interest in any materials discussed in this article.FINANCIAL DISCLOSURE(S)The author(s) have no proprietary or commercial interest in any materials discussed in this article. |
| Author | Vora, Robin A Bhatti, M Tariq Shah, Ronak Gilbert, Aubrey Patel, Amar P Zheng, Xuwen |
| Author_xml | – sequence: 1 givenname: Ronak surname: Shah fullname: Shah, Ronak organization: Renaissance School of Medicine at Stony Brook University, Stony Brook, NY – sequence: 2 givenname: Xuwen surname: Zheng fullname: Zheng, Xuwen organization: Renaissance School of Medicine at Stony Brook University, Stony Brook, NY – sequence: 3 givenname: Amar P surname: Patel fullname: Patel, Amar P organization: Kaiser Permanente Northern California, Oakland, CA – sequence: 4 givenname: M Tariq surname: Bhatti fullname: Bhatti, M Tariq organization: Kaiser Permanente Northern California, Roseville, CA – sequence: 5 givenname: Aubrey surname: Gilbert fullname: Gilbert, Aubrey organization: Kaiser Permanente Northern California, Vallejo, CA – sequence: 6 givenname: Robin A surname: Vora fullname: Vora, Robin A email: robin.vora@kp.org organization: Kaiser Permanente Northern California, Oakland, CA. Electronic address: robin.vora@kp.org |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38154618$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LAzEQhoMottb-AQ-So5ddJ0mbzXori19QLIgKnpY0ndgtu0lNsof-exes4OkZ3nkYmPeCnDrvkJArBjkDJm93uQ-Ycg5c5IznAMUJGfOZVJmcCzj9N4_INMYdADDFpSzgnIyEYvOZZGpMPit0KeiWvmJq3MBFSBgOdGVM28fGuzv60cR-WKz6ZHyHkdrgO7qgSx2-kL74kLYYHK1021gfXKNp5bdDeknOrG4jTo-ckPeH-7fqKVuuHp-rxTLbc8ZSxueGWSVMARuDWJSmRA6FYMIiFwatHT5gxQBUWmOplTGmNEyDUcWsVGs-ITe_d_fBf_cYU9010WDbaoe-jzUvQTEuuIRBvT6q_brDTb0PTafDof6rg_8AxapmFQ |
| ContentType | Journal Article |
| Copyright | Copyright © 2023. Published by Elsevier Inc. Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2023. Published by Elsevier Inc. – notice: Copyright © 2023 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
| DBID | NPM 7X8 |
| DOI | 10.1016/j.oret.2023.12.007 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2468-6530 |
| ExternalDocumentID | 38154618 |
| Genre | Journal Article |
| GroupedDBID | 0R~ 53G AALRI AAXUO ABJNI ACGFS AFJKZ AFTJW AGCQF AITUG ALMA_UNASSIGNED_HOLDINGS APXCP EBS EFKBS FDB M41 NPM O9- ROL 7X8 |
| ID | FETCH-LOGICAL-p211t-25c1f83c70dcee79c9e207313fe23ceff53017ff5e8aae9a8ccc9c1a0c87498b2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 10 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001299805000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2468-6530 |
| IngestDate | Sat Sep 27 20:56:01 EDT 2025 Mon Jul 21 05:47:18 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | embolic stroke retinal vascular disease central retinal artery occlusion (CRAO) |
| Language | English |
| License | Copyright © 2023. Published by Elsevier Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p211t-25c1f83c70dcee79c9e207313fe23ceff53017ff5e8aae9a8ccc9c1a0c87498b2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 38154618 |
| PQID | 2908123260 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2908123260 pubmed_primary_38154618 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-06-01 |
| PublicationDateYYYYMMDD | 2024-06-01 |
| PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Ophthalmology retina |
| PublicationTitleAlternate | Ophthalmol Retina |
| PublicationYear | 2024 |
| SSID | ssj0001826670 |
| Score | 2.321591 |
| Snippet | To assess visual acuity (VA) outcomes in a large cohort of patients diagnosed with non-arteritic central retinal artery occlusion (CRAO), and to ascertain... To assess visual acuity (VA) outcomes in a large cohort of patients diagnosed with nonarteritic central retinal artery occlusion (CRAO), and to ascertain... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 566 |
| Title | Central Retinal Artery Occlusion: Visual Outcomes from A Large Northern California Cohort |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38154618 https://www.proquest.com/docview/2908123260 |
| Volume | 8 |
| WOSCitedRecordID | wos001299805000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPBaTZq2SbyILC4e9oWorKeSpgkuSLtut4L_3knbZU-C4CWFPmiYJpnJN_P1Q-hKmTQUNmBe4BNoeMI9RVnkMQF7AaKThNtKtaTHBwMxHstRA7gVTVnlYk2sFuo01w4jv_ElOC9w_xG5m356TjXKZVcbCY1V1GIQyriSLj4WS4wFYueo0ovzHcEoChlpeDN1iZcjCl47_fAKEST89yiz8jbd7f_2cwdtNXEmvq8Hxi5aMdke2ug3mfR99NbAuvjJcZ7rO83sGw-1_igdgnaLXydFCReG5RzebArsmChY4Z6rHcdVvsfMMrwkd-FO_g5nD9BL9-G58-g1MgveFHZ_c88PNbWCaU5S8Jhcaml8mPiUWeMzbawFs1EOByOUMlIJrbXUVBEteCBF4h-itSzPzDHCQgVJSogKU_D61qeJZJqKSIUsIopr1kaXC6PFMIxdbkJlJi-LeGm2NjqqLR9P6_9txBBUhEFExckfnj5Fm_BBg7qY6wy1LExic47W9dd8UswuqvEB7WDU_wGn2sSL |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Central+Retinal+Artery+Occlusion%3A+Visual+Outcomes+from+a+Large+Northern+California+Cohort&rft.jtitle=Ophthalmology+retina&rft.au=Shah%2C+Ronak&rft.au=Zheng%2C+Xuwen&rft.au=Patel%2C+Amar+P&rft.au=Bhatti%2C+M+Tariq&rft.date=2024-06-01&rft.issn=2468-6530&rft.eissn=2468-6530&rft.volume=8&rft.issue=6&rft.spage=566&rft_id=info:doi/10.1016%2Fj.oret.2023.12.007&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2468-6530&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2468-6530&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2468-6530&client=summon |